在治疗阿片类药物使用障碍的人群中使用和对大麻素的看法
Christopher Kudrich1, Rebecca Chen2, Yuan Meng3
1Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Addiction Institute of Mount Sinai, 1399 Park Ave, Room 3-330, New York, NY, 10029, USA. ckudrich@mssm.edu.
Harm reduction journal
|July 17, 2024
概括
Cannabidiol (CBD) 的使用与对其合法性和治疗潜力的更积极的看法有关,在阿片类药物使用障碍 (OUD) 患者中. 许多患者已经使用CBD治疗各种症状,并作为减少危害的策略.
科学领域:
- 成 药物 药物 药物 药物
- 大麻素研究 研究 大麻素研究
- 公共卫生 公共卫生
背景情况:
- 大麻醇 (CBD) 广泛使用,据称有健康益处,但其在阿片类药物使用障碍 (OUD) 患者中的感知和使用仍未得到充分研究.
- 了解患者对CBD的看法至关重要,因为CBD越来越受欢迎,并在管理OUD症状方面发挥潜在作用.
研究的目的:
- 调查OUD治疗的个人中CBD使用的程度.
- 探索CBD在这个人群中被使用的目的.
- 在OUD治疗背景下,比较CBD在用户和非用户之间对CBD的看法.
主要方法:
- 在西奈山上研究所接受OUD治疗的587名个人进行了一项调查.
- 该调查包括有关人口统计,阿片类药物使用,CBD使用和CBD的看法等问题.
- 使用顺序逻辑回归来比较CBD用户和非用户之间的感知,并根据年龄和种族进行调整.
主要成果:
- 在550名完成者中,129人 (23%) 报告使用CBD治疗焦虑,疼痛,睡眠,抑郁或其他原因.
- 很大一部分使用者 (17.1%) 使用CBD来控制成,41.9%用于缓解阿片类药物戒断症状.
- CBD用户对其合法性,社会接受度和治疗潜力表现出更积极的看法,包括其未来在成管理中的作用.
结论:
- CBD的使用与对其在OUD患者中管理成方面的潜在作用的更进步观点有关.
- 患者正在积极使用CBD来控制OUD的症状和减少OUD的危害.
- 患者的观点对于未来的研究和治疗策略至关重要,涉及OUD的CBD.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
209
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
209
Analgesia and Pain Management
561
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
561
Opioid Analgesics: Synthetic and Semisynthetic Opioids
266
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
266
Opioid Analgesics: Morphine and Other Natural Cogeners
219
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
219
Opioid Receptors: Overview
686
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
686
Drug Abuse and Addiction: Pharmacological Phenomena
459
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
459


